Manufacturing capacity, regulatory requirements and market demand are important factors that may impact this timeline
Response to semaglutide varies significantly among individuals based on genetic factors, baseline metabolic state, and GLP-1 receptor expression
On the other hand, it may take some time to see the tangible fruits of your efforts
nevertheless responses to treatment can vary from person to person
Additionally, patients with T2DM and comorbid cardiovascular or chronic kidney disease who received once-daily oral semaglutide (14 mg) exhibited a cardiovascular safety profile similar to that of the subcutaneous form [49]
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, place-bo-controlled, phase 3 trial